Osteoid Osteoma Radiofrequency Ablation Treatment using a Kirschner Wireguided with a Scope: A Case Report and Literature Review

Vol 5 | Issue 3 | September – December 2019 | page: 2-4 | Dr. Francisco de Assis Serra Baima Filho.

Author: Francisco de Assis Serra Baima Filho [1].

[1] Department of Orthopedic Oncology, Aldenora Bello Oncology Institute of Maranhao, Brazil.

Address of Correspondence
Dr. Francisco de Assis Serra Baima Filho,
Department of Orthopedic Oncology, Aldenora Bello Orthopedic Oncology Institute of Maranhao (IMOAB), Brazil.
E-mail: assisbaima@gmail.com


Introduction: Osteoid osteoma is a benign tumor and is the third most common bone tumor. It is <2cm and characterized by very intense clinical pain at night which lets up after taking two nonsteroid anti-inflammatory drugs. Conventionally, the surgical treatment performed was resection or curettage. At present, the recommended treatment is computed tomography (CT)-guided radio frequency due to the high efficacy rate and low comorbidity.
Case Report: A 29-year-old male patient diagnosed with an osteoid osteoma in a small right femoral trochanter. Due to the location of the tumor, we opted for a percutaneous treatment, but it was not possible to be submitted to CT-guided radio frequency due to the high costs. Thus, the scope-guided Kirschner wire radioablation technique was developed.
Discussion: At present, CT-guided radio frequency ablation is the most commonly used method due to its safety, high efficacy (over 90%), and minimally invasive. However, there are disadvantages: Problems with sterility of the radiological set, radiation, and high risk of thermal the skin and soft tissue necrosis. New treatment methods are under development, but they are even more costly.
Conclusion: Due to its high costs, many patients, especially from underdeveloped countries, donot undergo this treatment and are reserved to open surgical treatment with resection or curettage. Therefore, the development of low-cost minimally invasive percutaneous techniques is necessary.
Keywords: Osteoid osteoma (MeSH ID: D010017), case report (MeSH ID: D002363), rare diseases (MeSH ID: D035583), literature review (MeSH ID: D016454).


1. Göksel F, Aycan A, Ermutlu C, Gölge UH, Sarisözen B. Comparison of radiofrequency ablation and curettage in osteoid osteoma in children. Acta Ortop Bras 2019;27:100-3.
2. Gurkan V, Erdogan O. Foot and ankle osteoid osteomas. J Foot Ankle Surg 2018;57:826-32.
3. Rinzler ES, Shivaram GM, Shaw DW, Monroe EJ, Koo KS. Microwave ablation of osteoid osteoma: Initial experience and efficacy. Pediatr Radiol 2019;49:566-70.
4. Hage AN, Chick JF, Gemmete JJ, Grove JJ, Srinivasa RN. Percutaneous radiofrequency ablation for the treatment of osteoid osteoma in children and adults: A comparative analysis in 92 patients. Cardiovasc Intervent Radiol 2018;41:1384-90.
5. Santiago E, Pauly V, Brun G, Guenoun D, Champsaur P, Le Corroller T. Percutaneous cryoablation for the treatment of osteoid osteoma in the adult population. Eur Radiol 2018;28:2336-44.
6. Shields DW, Sohrabi S, Crane EO, Nicholas C, Mahendra A. Radiofrequency ablation for osteoid osteoma-recurrence rates and predictive factors. Surgeon 2018;16:156-62.
7. Cuesta HE, Villagran JM, Horcajadas AB, Kassarjian A, Caravaca GR. Percutaneous radiofrequency ablation in osteoid ostema: Tips and tricks in special scenarios. Eur J Radiol 2018;102:169-75.
8. Miyazaki M, Saito K, Yanagawa T, Chikuda H, Tsushima Y. Phase I clinical trial of percutaneous cryoablation for osteoid osteoma. Jpn J Radiol 2018;36:669-75.
9. Erdogan O, Gurkan V. Hand osteoid osteoma: Evaluation of diagnosis and treatment. Eur J Med Res 2019;24:1-5.
10. Doyle AJ, Graydon AJ, Hanlon MM, French JG. Radiofrequency ablation of osteoid osteoma: Aiming for excellent outcomes in an Australasian context. J Med Imaging Radiat Oncol 2018;62:789-93.

How to Cite this article:  de Assis Serra Baima Filho F | Osteoid Osteoma Radiofrequency Ablation Treatment using a Kirschner Wire-guided with a Scope: A Case Report and Literature Review | Journal of Bone and Soft Tissue Tumors | Sep-Dec 2019; 5(3): 2-4.

(Abstract Full Text HTML) (Download PDF)